E-mail this page Printer Friendly Version RSS E-mail Alerts View contacts Download Financial Tear Sheet 

Press Release

Printer Friendly Version View printer-friendly version
<< Back
Quest Diagnostics Acquires ReproSource, Extending Into Advanced Fertility Diagnostics
Bolsters Quest's leadership in advanced diagnostics for women's and reproductive health

SECAUCUS, N.J. and WOBURN, Mass., Sept. 24, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has acquired ReproSource, a national leader in specialty fertility diagnostic services.

Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)

About 10 percent of women of child-bearing age in the United States have difficulty getting or staying pregnant, according to the Centers for Disease Control and Prevention. Woburn, Mass-based ReproSource provides a range of advanced diagnostic services, such as genetics-based ovarian health and recurrent pregnancy loss assessments, to help patients identify and surmount obstacles to fertility and pregnancy.

"Our acquisition of ReproSource delivers on our accelerate growth strategy, particularly in advanced diagnostics, and our goal to deliver the broadest access to diagnostic innovation," said Steve Rusckowski, Chairman, President and CEO, Quest Diagnostics. "ReproSource is recognized for evidence-based expertise in reproductive diagnostics and will extend our breadth of services for providers and their patients."

Quest plans to offer ReproSource's services nationally as part of its comprehensive women's health and reproductive offerings for obstetricians, gynecologists, fertility specialists and other physicians.

Quest is a leader in advanced diagnostics services that help guide women and their physicians through the reproductive journey. These services include the company's proprietary QNatal™ noninvasive prenatal and QHerit™ carrier genetic screening services.

Additional terms were not disclosed.

About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/quest-diagnostics-acquires-reprosource-extending-into-advanced-fertility-diagnostics-300716404.html

SOURCE Quest Diagnostics

Kim Gorode, Quest Diagnostics (Media): 973-520-2800, or Shawn Bevec, Quest Diagnostics (Investors): 973-520-2900